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Abstract: Obstructive sleep apnea (OSA) is associated with high cardiovascular morbidity and 
mortality. Recent studies have shown that it is associated with atherosclerosis and left ventricular 
dysfunction markers. The aim of this study was to assess the cardiovascular effects of OSA 
depending on its severity, in patients without clinically diagnosed cardiovascular disease. One 
hundred thirty newly diagnosed, nondiabetic OSA patients (mean age 49 ± 10 years), without 
vasoactive treatment were included. They underwent clinical and ambulatory blood pressure 
measurements, echocardiography, carotid ultrasound examination, and a carotid–femoral pulse 
wave velocity (PWV) measurement. Seventy-five percent of the subjects were hypertensive 
according to the clinical or ambulatory measurement. More patients with the most severe forms 
(respiratory disturbance index 37/hour) had a nondipper profile (52% vs 34%; P = 0.025) 
and their left ventricular mass was higher (40 ± 7 vs 36 ± 8 g/m, p = 0.014). This last parameter 
was independently and inversely associated with mean nocturnal oxygen saturation (P = 0.004). 
PWV and carotid intima-media thickness did not differ between one OSA severity group to 
another, but the prevalence of carotid hypertrophy was higher when mean SaO2 was below 93.5% 
(29.5 vs 16%; P = 0.05). Our study shows that in OSA patients without clinically diagnosed 
cardiovascular disease, there is a significant left ventricular and arterial effect, which is even 
more marked when OSA is severe.
Keywords: obstructive sleep apnea, hypertension, left ventricular hypertrophy, intima-media 
thickness, arterial stiffness
Introduction
Obstructive sleep apnea (OSA) is a common but underdiagnosed disease1 that causes 
increased cardiovascular morbidity and mortality, including arterial hypertension 
(HT), coronary heart disease, heart rhythm and conduction disorders, heart failure, 
and stroke.2–12
Although OSA is often associated with certain cardiovascular risk factors such 
as HT, obesity, diabetes, and dyslipidemia, it is legitimate to mention the direct role 
that OSA plays in the development of atherosclerosis. In fact, repeated episodes of 
hypoxia, hypercapnia, microarousals, and changes in intrathoracic pressure trigger 
pathophysiological mechanisms such as sympathetic hyperactivity,13–15 oxidative 
stress,16 systemic inflammation,17 hypercoagulability,18 and even endothelial 
dysfunction.19 And all these abnormalities combine chronically to bring about 
the development of vascular lesions. Ultrasonography – a noninvasive, quick and 
reproducible technique – can be used to evaluate the atherosclerotic process at 
an early stage.20 It analyzes vascular remodeling, measures the parietal thickness Vascular Health and Risk Management 2009:5 1064
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(intima-media thickness [IMT]) and detects atheromatous 
plaques. Like IMT and carotid plaques, carotid–femoral pulse 
wave velocity (PWV) is an early and independent marker of 
cardiovascular morbidity and mortality, notably coronary and 
cerebral morbidity and mortality.21–23 PWV is a noninvasive 
way of assessing aortic stiffness. The large arteries play a 
crucial role in cardiac structure so increased arterial stiff-
ness contributes independently to arterial pressure and to an 
increase in left ventricular afterload, thereby promoting left 
ventricular hypertrophy (LVH).24
A few studies have focused on structural and functional 
modifications to the large arteries in OSA, with the majority 
of them reporting increases in carotid IMT and PWV .25–34 
Similarly, some studies have found a link between OSA and 
LVH.35–38 The link that connects OSA to these cardiovascular 
abnormalities remains ambiguous due to the frequent pres-
ence of confounding factors in the studies.
We performed our study on a large sample of patients 
with newly diagnosed and untreated OSA, without any known 
cardiovascular disease or vasoactive treatment. The main aim 
was to assess arterial structural and functional modifications, as 
well as remodeling of the left ventricle (LV), in this population. 
To the best of our knowledge, no study has simultaneously ana-
lyzed these three cardiovascular abnormalities in OSA patients 
without clinically diagnosed cardiovascular disease.
Materials and methods
Study population
The patients included in the study were referred to the 
Sleep Laboratory at the University Hospital of Grenoble 
(France) for symptoms indicating OSA between November 
2001 and July 2007. The diagnosis of OSA was confirmed 
using polysomnography or ventilation polygraphy. We 
did not include patients if they presented a known cardio-
vascular disease including HT, any pathology affecting 
arterial blood pressure (BP) regulation (such as heart failure, 
Parkinson’s disease and heart or kidney transplantation), atrial 
fibrillation or frequent extrasystole (10/min), chronic respi-
ratory insufficiency or previous treatment of OSA by means 
of nasal continuous positive airway pressure (nCPAP), maxil-
lofacial surgery or a mandibular advancement prosthesis (oral 
appliance). We excluded diabetic patients (fasting glycemia 
7.0 mmol/L or antidiabetic treatment), patients for whom 
the 24-hour ambulatory BP monitoring (ABPM) was invalid 
and patients who were on vasoactive drugs. Ethical approval 
was obtained from the local ethics committee and all of the 
participants gave their informed consent. The registration 
number for this study is NCT00764218.
Blood pressure and heart rate 
measurements
Clinical BP was measured by mercury sphygmomanometer 
on three occasions in line with European Society of 
Hypertension–European Society of Cardiology guidelines.39 
Systolic BP (SBP) and diastolic BP (DBP) were assessed. 
Pulse pressure (PP) was calculated using the following 
formula: PP = SBP minus DBP. Clinical HT was defined 
as a clinical SBP 140 mmHg and/or a clinical DBP 
 90 mmHg.39 Increased clinical PP was defined as 
PP  65 mmHg.40 Clinical heart rate (HR) was measured 
by pulse palpation (30 seconds) after the third measurement 
of BP in a supine position.
ABPM was carried out with a Spacelabs 90207® 
device (Spacelabs International, Redmond, WA, USA). 
Measurements were taken every 15 minutes over 24 hours. 
Daytime (07:00 to 22:00) HT was defined as daytime 
SBP  135 mmHg and/or daytime DBP  85 mmHg, and 
nocturnal (22:00 to 07:00) HT as nocturnal SBP  120 mmHg 
and/or nocturnal DBP  70 mmHg.39 Nondipping status was 
defined as a nocturnal BP reduction of 10%.
Respiratory measurements
Full polysomnography was performed in 94 of the 
130 patients (72%). Continuous recordings were taken with 
electrode positions C3/A2-C4/A1-Cz/01 of the international 
10–20 Electrode Placement System, eye movements, chin 
electromyogram and ECG modified V2 lead. Sleep was 
scored manually according to standard criteria.41 Airflow 
was measured using nasal pressure associated with the sum 
of buccal and nasal thermistor signals. Respiratory efforts 
were monitored with abdominal and thoracic bands. An 
additional respiratory effort signal (ie, pulse transit time) 
was recorded concurrently. Pulse transit time allowed us 
to identify “autonomic activations”, and as a consequence, 
microarousals.42 We were thus able to use the same rules 
and definition for hypopnea whatever the diagnostic method 
used for the diagnosis of sleep apnea. Oxygen saturation 
(SaO2) was measured using a pulse oximeter (Biox-Ohmeda 
3700®; Ohmeda, Liberty Corner, NJ, USA). The same vari-
ables were measured in the remaining 36 patients, except 
for sleep variables which were not recorded. Apnea was 
defined as a complete cessation of airflow for 10 seconds, 
and hypopnea as a 50% reduction in the nasal pressure 
signal or a 30%–50% decrease associated with either oxygen 
desaturation of 3% or an arousal (defined according to the 
Chicago report or by autonomic activations on pulse transit 
time), both lasting for 10 seconds.42,43 Apnea was classified Vascular Health and Risk Management 2009:5 1065
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as obstructive, central or mixed according to the presence or 
absence of respiratory efforts. The classification of hypopnea 
as obstructive or central was based on the pulse transit time 
signal and the shape of the inspiratory part of nasal pressure 
(flow limited aspect or not). The respiratory disturbance 
index (RDI) was calculated and defined as the number of 
episodes of apnea and hypopnea per hour of sleep (full poly-
somnography) or per hour of recording (polygraphy without 
electroencephalogram recording). In our study, a diagnosis of 
OSA was retained if RDI was 15 per hour. Subjects were 
split into two groups depending on the severity of their OSA, 
using the median RDI: group A (RDI  37/hour, N = 65) and 
group B (RDI  37/hour, N = 65). In an additional analysis, 
they were then split according to the median of the mean 
nocturnal SaO2: group 1 (SaO2  93.5%, N = 65) and group 
2 (SaO2  93.5%, N = 65).
echocardiography
The echocardiogram was carried out using an HP Sonos 
2500® (Hewlett Packard, Santa Clara, CA, USA) machine 
equipped with a 2.5 MHz probe. The examination was per-
formed in M-mode with 2D guidance in the long axis of the 
left parasternal view. LV internal end-diastolic (LVD) and 
end-systolic diameters, as well as interventricular septum 
and posterior wall (LVPW) thicknesses, were measured over 
five consecutive cycles. Systolic function was assessed by 
the LV ejection fraction (LVEF) according to the Teicholz 
formula. LV mass (LVM) was measured according to the 
Penn convention using the Devereux formula and was 
normalized for body surface area and height2.7 to derive the 
LV mass index (LVMI and LVMI-height2.7).44,45 LVH was 
defined as an LVMI of  111 g/m2 or  50 g/m2.7 in men and 
of 106 g/m2 or 47 g/m2.7 in women.46,47 LV geometry was 
analysed according to the presence or absence of LVH and the 
calculated relative parietal thickness at the end of ventricular 
diastole (RWT = 2 × LVPW/LVD). All echocardiograms 
were recorded by the same experienced operator. We were 
able to perform a complete LV geometry analysis in 116 of 
the 130 patients (89%).
Carotid ultrasonography
B-mode ultrasonography was performed using an HP Sonos 
2500® (Hewlett Packard) machine using a sectorial 7.5 MHz 
probe. The method used to determine the mean common 
carotid IMT and luminal diameter has been previously 
described.48 Both common carotid arteries were studied con-
secutively in the long axis with a probe incidence allowing 
good quality images. The IMT was defined as the distance 
separating the most internal parts of these lines and the 
luminal diameter by the distance between the blood–intima 
interfaces on the anterior and posterior walls. The images were 
recorded in end-diastole and then analyzed by specific vali-
dated software (TIMC laboratory, CHU Grenoble, France). 
IMT and diameter measurements were carried out on areas 
free of atheroma and then averaged. The IMT and luminal 
diameter values for any given subject were the mean values 
for the two common carotid arteries. Carotid wall hypertro-
phy was defined as a common carotid IMT above 0.8 mm.49 
A plaque was defined as an echogenic structure encroaching 
into the vessel lumen with a distinct area and with an IMT 
more than 50% greater than those of the neighboring sites. 
Carotid ultrasonography was performed by two operators who 
were blinded to the other study data. The analysis of carotid 
parameters using the specific software was performed by the 
same operator throughout the entire study.
Aortic pulse wave velocity
To determine the carotid-femoral PWV , two pulse transduc-
ers were fixed on the skin over the right common carotid 
and femoral arteries. The time delay was measured with a 
Complior® device (Artech Medical, Pantin, France), between 
the feet of simultaneously recorded pulse waves and aver-
aged over 10 consecutive cycles. The carotid-femoral PWV 
was calculated as the distance between the arterial sites 
divided by the time delay. Increased PWV was defined 
as PWV  12 m/second.39
Biological parameters
All of the subjects had plasma assays of total cholesterol 
(enzymatic colorimetry, normal: 4.62–7.04 mmol/L), triglyc-
erides (enzymatic colorimetry, normal: 0.63–2.58 mmol/L), 
high-density lipoprotein (HDL) cholesterol (enzymatic 
colorimetry, normal: 1.0–1.62 mmol/L), low-density lipo-
protein (LDL) cholesterol (Friedwald formula, normal: 
2.60–4.67 mmol/L), glucose (enzymatic method, normal: 
3.8–5.8 mmol/L) and creatinine (enzymatic colorimetry, 
normal: 62–106 µmol/L).
Statistical analysis
Statistical analyses were performed using SPSS software 
(SPSS Inc, Chicago, IL, USA). We assessed the normality 
of data distribution. Continuous data were expressed as 
mean ± standard deviation (SD). Relationships between 
continuous variables were evaluated using Pearson’s 
correlation analysis when data were normally distributed and 
using Spearman’s correlation analysis when they were not Vascular Health and Risk Management 2009:5 1066
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normally distributed. Noncontinuous variables, expressed 
as percentages, were compared using a Chi-squared test. 
Comparisons between groups for continuous variables were 
made using a Student’s t-test (or a Mann–Whitney U test 
when the data were not normally distributed). We performed 
multivariate analysis using stepwise regression. Variables 
included in our analysis were all the variables significantly 
(P  0.05) associated with the explained variable using uni-
variate analysis. We considered values of P  0.05 significant 
for all analyses. We have chosen to include all P values under 
0.20 in the tables.
Results
We included 130 patients (109 men, 84%), with a mean age 
of 49 ± 10 years. The general characteristics of the popula-
tion are presented in Table 1. Most of the patients exhibited 
moderate to severe OSA (63 of the 130 subjects (48%) had a 
RDI of 30–50 per hour, and 31 (24%) had a RDI upper than 
50 per hour). Body mass index (BMI) was 26.5 ± 3 kg/m2, 
73 patients (56%) were overweight and 15 (11.5%) were 
obese. Groups A and B were comparable in terms of age, 
sex, smoking status and all biological parameters. Patients 
with RDI over 37 per hour (ie, Group B) had a significantly 
higher BMI.
Clinical BP and ABPM parameters, as well as HR, did 
not vary from group to group (Table 1). Forty-five patients 
(35%) had clinical HT, 66 (51%) had diurnal HT, and 89 
(68%) had nocturnal HT. In total, 98 patients (75%) were 
hypertensive measured clinically or with ABPM. Out of the 
45 patients presenting clinical HT, grades were as follows: 
28 HT grade 1 (62%), 13 HT grade 2 (29%) and four HT 
grade 3 (9%). Eight subjects (18%) had isolated systolic 
HT, 15 (33%) had isolated diastolic HT, and 22 (49%) 
had systolo-diastolic HT. Fifty-five patients (42%) had 
a nondipper profile for either SBP or DBP. There was a 
trend for a higher prevalence of clinical HT in group B 
(41% vs 28%, respectively; P = 0.07) than in group A, and 
a nondipper profile was more common in the most severe 
cases of OSA (Table 2).
Arterial parameters are presented in Table 2. There are 
no significant differences between groups A and B in any 
of these parameters. Carotid IMT and PWV were positively 
correlated with age (P  0.0001), clinical SBP, DBP, and 
PP (P  0.0001 for all but the correlation between IMT and 
DBP of P  0.01), as well as with all BP parameters mea-
sured using ABPM (P  0.05). Carotid IMT was correlated 
with mean SaO2 (r = -0.21, P = 0.017; Figure 1) but PWV 
and PP were not correlated with any respiratory parameters. 
Clinical PP was positively correlated with age (r = 0.19, 
P = 0.03) and carotid IMT, PWV and clinical PP correlated 
with each other. In a multivariate analysis, IMT and PWV 
were independently associated with age and with clinical SBP 
(P  0.0001). Clinical PP was independently associated with 
PWV (P  0.0001) and IMT (P = 0.005).
Patients presenting carotid parietal hypertrophy were 
older, had a higher clinical SBP and presented more severe 
OSA (Table 3). Subjects with carotid atheromatous plaques 
were older (P  0.0001), presented higher clinical SBP and 
DBP (P  0.001), and higher total (P = 0.018) and LDL 
(P = 0.028) cholesterol.
All of the echocardiographic parameters are summa-
rized in Table 2. LVEF did not change from group to group 
depending on the severity of the OSA. LVH was present in 
5% to 9.5% of the patients depending on the criteria chosen 
(LVMI or LVMI-height2.7), with no significant difference 
between the two groups. Patients with the most severe OSA 
had significantly higher LV wall thickness, LVM (before 
and after indexation) and RWT. LVMI-height2.7 was signifi-
cantly correlated with age (r = 0.19, P = 0.04), clinical SBP 
(r = 0.25, P = 0.006), and DBP (r = 0.22, P = 0.02), diurnal 
and nocturnal SBP and PP (P  0.05), mean nocturnal SaO2 
(r = -0.27, P = 0.003), minimal SaO2 (r = -0.19, P = 0.036) 
and SaO2  90% (r = 0.23, P = 0.011), but not with RDI. 
LVMI-height2.7 was also correlated with IMT (r = 0.19, 
P = 0.038) and PWV (r = 0.18, P = 0.05). In a multivariate 
analysis, LVMI-height2.7 was independently correlated with 
clinical SBP (β = -0.25, P = 0.01) and mean nocturnal SaO2 
(β = 0.23, P = 0.004).
Patients with mean SaO2  93.5% (Group 1) were older 
(P = 0.001) and had a higher BMI (P = 0.003). They also 
tended to have worse HT as evaluated both clinically and 
measured using ABPM (Table 4) and presented significantly 
higher LVMI-height2.7 (P = 0.003) (Figure 2), as well as a 
greater prevalence of carotid parietal hypertrophy (29.5% vs 
16%, P = 0.05).
Discussion
HT: a common disease in OSA
The prevalence of HT in OSA patients is estimated to be 
nearly 50%.50 Although the link between the two pathologies 
was long disputed due to the numerous confounding factors, 
OSA is now recognized as one of the causes of secondary 
HT.39,51 In our study, 75% of patients were hypertensive, 
although at inclusion, none of them were known to be 
hypertensive. In the general population, the prevalence of 
undiagnosed HT is around 25%,52 which is three times Vascular Health and Risk Management 2009:5 1067
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lower than in our population. Our results show the extent to 
which HT is under-diagnosed in OSA patients. They also 
serve as a reminder of the utility of ABPM, which is a rec-
ommended technique in this pathology.39 In our study, this 
OSA-associated HT showed the following characteristics: 
predominantly nocturnal HT associated with a high preva-
lence of nondipper status and primarily diastolic HT. This is 
in line with the data found in the literature. We did not find 
any difference in BP values according to the severity of the 
OSA. This is certainly linked to the fact that, despite high 
prevalence of HT, the population studied was very moderately 
hypertensive (62% grade 1 HT). In fact, we were studying 
an OSA population without clinically diagnosed cardiovas-
cular disease, which was consequently not greatly affected 
by severe HT.
From a pathophysiological point of view, episodes of 
apnea and hypopnea are responsible for changes in BP. 
The occurrence of a cortical microarousal leads to a hyper-
tensive peak.53,54 Moreover, repeated episodes of hypoxia 
and hypercapnia trigger pathophysiological mechanisms 
including sympathetic hyperactivity.13,55 and the secre-
tion of vasoactive substances.56,57 Finally, each apnea is 
accompanied by a cycle of desaturation and reoxygenation 
which leads to the production of free radicals,58 systemic 
inflammation,17 and coagulation abnormalities.18 These 
biochemical and cellular modifications contribute to endo-
thelial dysfunction19,59 and atherosclerotic degeneration. 
It has been hypothesized that chronic hypoxia has an effect 
on vascular remodeling on the basis of results from animal 
and tissue culture experiments.60,61
Table 1 General, hemodynamic, biological, and respiratory characteristics of the global population and according to the severity of 
OSA (RDi)
Total  
(N = 130)
Group A  
RDI  37 (N = 65)
Group B  
RDI  37 (N = 65)
P value
Age (years) 49 ± 10 48 ± 10 49 ± 10 NS
Gender (% men) 84 80 88 NS
BMi (kg/m²) 26.5 ± 3 25.6 ± 3 27.5 ± 3.5 0.001
Active smoking (N, %) 26 (20) 14 (21) 12 (18) NS
Clinic SBP (mmHg) 131 ± 16 131 ± 18 132 ± 14 NS
Clinic DBP (mmHg) 86 ± 10 85 ± 11 87 ± 10 NS
Clinic PP (mmHg) 45 ± 11 46 ± 12 44 ± 10 NS
Clinic HR (bpm) 65 ± 10 65 ± 10 65 ± 10 NS
Daytime SBP (mmHg) 128 ± 14 127 ± 13 128 ± 15 NS
Daytime DBP (mmHg) 84 ± 8 84 ± 7 83 ± 9 NS
Nighttime SBP (mmHg) 113 ± 12 111 ± 12 114 ± 13 NS
Nighttime DBP (mmHg) 72 ± 8 71 ± 8 73 ± 8 NS
Total cholesterol (mmol/L) 5.16 ± 1.03 5.32 ± 1.06 5.06 ± 1.01 NS
LDL cholesterol (mmol/L) 3.22 ± 0.86 3.35 ± 0.91 3.02 ± 0.77 NS
HDL cholesterol (mmol/L) 1.55 ± 0.39 1.57 ± 0.37 1.54 ± 0.4 NS
Triglycerides (mmol/L) 1.2 ± 0.56 1.17 ± 0.34 1.24 ± 0.67 0.09
Glucose (mmol/L) 5.02 ± 0.7 5.0 ± 0.8 5.04 ± 0.5 NS
Creatininemia (µmol/L) 88 ± 13 89 ± 15 86 ± 12 NS
RDi (/h)
Microarousal index (/h) 40 ± 17 28 ± 7 53 ± 14 0.0001
Mean nocturnal SaO2 (%) 35 ± 14 29 ± 9 42 ± 15 0.0001
Minimal nocturnal SaO2 (%) 93.5 ± 1.8 94 ± 1.6 93 ± 2 NS
SaO2  90% (%) 84 ± 6 85.5 ± 5 82.6 ± 7 0.006
5.7 ± 11.5 3.5 ± 10 8 ± 13 0.03
Note: Results are given as mean ± SD or percentage.
Abbreviation: BMI, body mass index; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HR, heart rate; NS, not significant; 
OSA, obstructive sleep apnea; PP, pulse pressure; RDi, respiratory disturbance index; SaO2, oxygen saturation; SaO2  90%, percentage of recording time spent at a SaO2  90%; 
SBP, systolic blood pressure; SD, standard deviation.Vascular Health and Risk Management 2009:5 1068
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OSA, carotid remodeling, and arterial 
stiffness
Carotid ultrasonography and evaluation of arterial stiffness 
are useful for the early detection of atherosclerosis at an 
asymptomatic stage.62,63 Increased carotid IMT is a marker 
of structural vascular damages whereas arterial stiffness, as 
estimated by PP and PWV , reflects functional modifications 
on the large arteries. In our study, carotid IMT, PP and PWV 
values were not very high compared to previous studies con-
ducted on apnea patients. This partly explains the absence of 
a significant difference between our two OSA severity groups 
for these arterial parameters. These “normal” values are 
probably due to the relatively low number of major vascular 
risk factors in our population.
Almost a quarter of patients presented carotid hypertrophy 
and 19% had carotid plaques. These values are particu-
larly high for a population potentially considered at low 
cardiovascular risk, according to the literature.64 Furthermore, 
carotid hypertrophy was more common in patients with 
the most severe OSA (mean SaO2  93.5%) and it was 
associated with worse respiratory parameters. In line with 
other studies,25–30,33 our results suggest that OSA contributes 
to the genesis of atherosclerosis. However, it remains to be 
formally demonstrated that the association between OSA 
and carotid hypertrophy is independent, as the confounding 
factors are numerous. A few studies state that OSA has a 
direct effect on IMT.25,28,30 However, most of these studies 
have significant limitations as they cover a large number of 
major vascular risk factors and subject numbers are low, 
eg, Silvestrini and colleagues studied a sample of 23 obese 
patients.25 Similarly, in the study by Schulz and colleagues, 
20% of patients were diabetic, 58% were dyslipidemic, and 
65% were hypertensive.30 In contrast, in our study, there were 
no diabetic patients, only 11.5% were obese, and only 7.5% 
were dyslipidemic. We recently published a study in 83 OSA 
patients after exclusion of the majority of confounding 
factors and found an independent association between IMT 
and SaO2, but only in normotensive subjects.28 In addition 
to the relatively low number of major vascular risk factors 
in our study, the relatively young age of the population and 
Table 2 Cardiovascular parameters in the global population and according to the severity of OSA (RDi)
Total  
(N = 130)
Group A  
RDI  37 (N = 65)
Group B  
RDI  37 (N = 65)
P value
Clinic hypertension (N, %) 45 (35) 18 (28) 27 (41) 0.07
Nondipper SBP (N, %) 49 (38) 18 (28) 31 (48) 0.015
Nondipper DBP (N, %) 37 (29) 13 (20) 24 (37) 0.026
Nondipper SBP or DBP (N, %) 55 (42) 22 (34) 34 (52) 0.025
LVeF (%) 58 ± 6 59 ± 6 57 ± 7 NS
iVS (mm) 8.5 ± 1 8.1 ± 1.1 8.8 ± 1.2 0.005
LVPw (mm) 9.0 ± 1.1 8.7 ± 1.2 9.2 ± 1.2 0.01
LVM (g) 168 ± 41 159 ± 41 178 ± 38 0.013
LVMi (g/m2) 87 ± 19 83 ± 20 90 ± 18 0.05
LVMi-height2.7 (g/m) 38 ± 8 36 ± 8 40 ± 7 0.014
LVH ind2.7 (N, %) 11 (9.5) 4 (7) 7 (12) 0.19
RwT (%) 36 ± 5.5 35 ± 4.6 37 ± 6 0.039
RwT  0.45 (N, %) 7 (6) 2 (3.5) 5 (8.5) 0.16
Clinic PP (mmHg) 45 ± 11 46 ± 12 44 ± 10 NS
increased clinic PP (N, %) 8 (6) 5 (7) 3 (4.5) NS
PwV (m/s) 9.1 ± 1.5 8.9 ± 1.6 9.2 ± 1.4 NS
increased PwV (N, %) 5 (8) 1 (1.5) 4 (6) 0.18
Carotid iMT (mm) 0.65 ± 0.15 0.64 ± 0.16 0.66 ± 0.13 NS
increased carotid iMT (N, %) 30 (23) 14 (21) 16 (25) NS
Carotid plaques (N, %) 25 (19) 13 (20) 12 (18) NS
Note: Results are given as mean ± SD or percentage.
Abbreviations: DBP, diastolic blood pressure; iMT, intima-media thickness; iVS, interventricular septum; LVeF,  left ventricular ejection fraction; LVH, left ventricular 
hypertrophy; LVM, left ventricular mass; LVMI, left ventricular mass index; LVPW, left ventricular posterior wall; NS, not significant; OSA, obstructive sleep apnea; 
PP, pulse pressure; PwV, pulse wave velocity; RDi, respiratory disturbance index; RwT, relative wall thickness; SBP, systolic blood pressure; SD, standard deviation.Vascular Health and Risk Management 2009:5 1069
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the recent diagnosis of the OSA potentially contributed to 
the exclusion of patients with more advanced atherosclerosis. 
However, our population must not be considered at low 
cardiovascular risk. This is well demonstrated by the high 
prevalence of carotid wall abnormalities.
We did not find a significant link between the severity 
of OSA and aortic stiffness. This is inconsistent with the 
findings of a number of other studies and can be explained 
first and foremost by the characteristics of the patients 
included.26,28,31,32,34 In fact, whilst in our study OSA was at a 
mild stage in most subjects and whilst there were few major 
vascular risk factors, the majority of other studies focusing 
on PWV looked at very severe OSA.31,32,34 Although carotid 
IMT appears to increase early on in the disease, the increase 
in arterial stiffness could be the consequence of prolonged 
exposure to OSA.
OSA and cardiac hypertrophy
Our results, like those of other studies, show a link between 
LVM and the severity of OSA.35–38,65–67 However, the 
prevalence of LVH was moderate in our study (9.5%), with 
no significant difference between the groups of differing 
OSA severity. In Noda and colleagues’ study, prevalence 
was nearly 40% but the patient population had been suffer-
ing from OSA for a longer period of time, was more obese 
and had worse HT.67 We can question the independence of 
the link between OSA and LVM, because OSA patients 
are more often hypertensive, obese or diabetic, and these 
are all well-characterized risk factors for LVH. Hedner 
and colleagues were the first to consider this link, showing 
that LVM was around 15% higher in normotensive OSA 
patients than in normotensive control subjects.65 Similarly, 
in the study by Cloward and colleagues, HT prevalence 
was 52% and that of LVH was 88%, suggesting that LVH 
cannot be explained by HT alone.37 However, the results 
of these studies must be analyzed with care because both 
included obese patients in whom it is well known that it 
is difficult to measure LVM by ultrasound. Furthermore, 
neither used ABPM, although 24-hour BP monitoring is 
more closely associated with LVM. Conversely, a more 
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recent study conducted by Niroumand and colleagues in 
533 OSA patients, in whom confounding factors were 
rigorously controlled for, showed that OSA was not directly 
involved in the LVM increase.36 In our study, the link 
between LVM and mean nocturnal SaO2 was independent 
of other factors, suggesting that OSA is directly involved 
in the occurrence of LVH.
From a pathophysiological point of view, the cardiac 
changes observed during OSA are linked to an increase in 
LV afterload, due to a number of different mechanisms. 
Thus, repeated episodes of nocturnal hypoxia and 
microarousals – as a result of the sympathetic hyperactivity 
that they cause – contribute to increase BP.15 On the other 
hand, the degree of negative intrathoracic pressure gener-
ated by inspiratory effort during OSA has the direct effect of 
raising transmural pressure and LV afterload, independently 
of BP.68–70 Finally, our study, like several others, suggests 
that arterial stiffness is a possible left ventricular remodel-
ing mechanism during OSA.71,72
Study limitations
The main limitation of our study is the absence of a control 
group. However, several studies have already shown that 
OSA patients present greater atherosclerotic and cardiac 
effects than healthy subjects. The aim of our prospective 
study performed on a large sample of newly diagnosed OSA 
patients was to determine whether the severity of OSA was 
associated with the cardiovascular effects independently of 
traditional major cardiovascular risk factors. As far as we 
know, this is the first study to have simultaneously evaluated 
structural and functional cardiovascular parameters in newly 
diagnosed OSA subjects.
It is difficult to assert that OSA is at an early stage. How-
ever, absence of known cardiovascular disease, particularly 
known hypertension, and absence of former OSA treatment 
is in favor of a recent disease.
We have used simplified techniques for assessing OSA 
diagnosis and severity in a subgroup of the included patients. 
However, in our study, LVM and carotid hypertrophy were 
Table 3 Factors related to carotid hypertrophy
Carotid hypertrophy  
(N = 30)
Normal IMT  
(N = 100)
P
Age (years) 55 ± 8 47 ± 10 0.0001
Clinic SBP (mmHg) 140 ± 18 128 ± 14 0.002
Mean nocturnal SaO2 (%) 92.6 ± 1.7 93.8 ± 1.7 0.002
Minimal nocturnal SaO2 (%) 82.2 ± 8.1 84.7 ± 5.5 0.055
SaO2  90% (%) 10 ± 16 5.5 ± 9.5 0.020
Note: Results are given as mean ± SD.
Abbreviations: iMT, intima media thickness; SaO2, oxygen saturation; SaO2  90%, percentage of recording time spent at a SaO2  90%; SBP, systolic blood pressure; 
SD, standard deviation.
Table 4 Cardiovascular anomalies according to the severity of OSA (mean nocturnal SaO2)
Group 1  
SaO2  93.5% (N = 68)
Group 2  
SaO2  93.5% (N = 62)
P value
Clinic hypertension (N, %) 27(40) 18 (29) 0.14
Clinic or ABPM hypertension (N, %) 55 (81) 43 (69) 0.09
Nondipper SBP or DBP 33 (48) 23 (38) 0.13
LVMi-height2.7 (g/m) 40 ± 8 36 ± 8 0.003
LVH ind2.7 (N, %) 8 (12) 3 (4.8) 0.12
Carotid iMT (mm) 0.67 ± 0.14 0.63 ± 0.15 0.13
increased carotid iMT (N, %) 20 (29.5) 10 (16) 0.05
Carotid plaques (N, %) 15 (22) 10 (16) NS
Note: Results are given as mean ± SD or percentage.
Abbreviations:   ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; iMT, intima media thickness; LVH, left ventricular hypertrophy; LVMi, left ventricular 
mass index; NS, not significant; OSA, obstructive sleep apnea; SaO2, oxygen saturation; SBP, systolic blood pressure; SD, standard deviation.Vascular Health and Risk Management 2009:5 1071
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mainly correlated with SaO2 parameters which are properly 
assessed by simplified sleep studies.
Conclusion
Our population of newly diagnosed OSA patients without 
clinically diagnosed cardiovascular diseases presented 
early signs of atherosclerosis and nascent cardiac damage. 
The severity of the OSA appeared to play more of a role 
in LV remodeling than in arterial modification. A more 
systematic study of functional and structural cardiac and 
arterial modifications in OSA patients could improve 
the stratification of their cardiovascular risk and help 
identify candidates for earlier and more aggressive OSA 
therapy.
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